Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 10
Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026 Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026. Duyuru • May 08
Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares. Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock. Duyuru • Apr 08
Innospec Inc. to Report Q1, 2026 Results on May 07, 2026 Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026 Duyuru • Mar 27
Innospec Inc., Annual General Meeting, May 08, 2026 Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States Duyuru • Jan 12
Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026 Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026 Duyuru • Nov 05
Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025 Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025. Duyuru • Oct 02
Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025 Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025 Duyuru • Jul 03
Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025 Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025 Duyuru • May 09
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025 Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025. Duyuru • Apr 04
Innospec Inc. to Report Q1, 2025 Results on May 08, 2025 Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 Duyuru • Mar 28
Innospec Inc., Annual General Meeting, May 09, 2025 Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United States Duyuru • Mar 11
Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares. Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. Duyuru • Jan 09
Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025 Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025 Declared Dividend • Nov 11
Dividend of US$0.79 announced Shareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Nov 06
Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023) Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Duyuru • Oct 04
Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024 Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024 Recent Insider Transactions • Aug 29
Executive VP & CFO recently sold €1.0m worth of stock On the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly €102 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by €1.5m. Reported Earnings • Aug 07
Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023) Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Jul 17
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 6.3% to €118. The fair value is estimated to be €96.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year. Duyuru • Jul 04
Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024 Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024 Buy Or Sell Opportunity • Jun 04
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 6.3% to €119. The fair value is estimated to be €98.70, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.7% in a year. Earnings are forecast to grow by 12% in the next year. Buy Or Sell Opportunity • May 12
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 8.9% to €122. The fair value is estimated to be €98.86, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 5.6% in a year. Earnings are forecast to grow by 12% in the next year. Duyuru • May 11
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024 Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024. Reported Earnings • May 10
First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023) First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Apr 10
Now 20% undervalued Over the last 90 days, the stock has risen 9.6% to €114. The fair value is estimated to be €143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 34%. Revenue is forecast to grow by 7.9% in 2 years. Earnings are forecast to grow by 25% in the next 2 years. Duyuru • Apr 06
Innospec Inc. to Report Q1, 2024 Results on May 09, 2024 Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024 Duyuru • Apr 03
Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025 On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement. Duyuru • Mar 29
Innospec Inc., Annual General Meeting, May 10, 2024 Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters. Recent Insider Transactions • Mar 08
Senior VP recently sold €290k worth of stock On the 1st of March, David Jones sold around 3k shares on-market at roughly €116 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €1.1m. Insiders have been net sellers, collectively disposing of €4.7m more than they bought in the last 12 months. Recent Insider Transactions • Feb 28
President recently sold €1.1m worth of stock On the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly €115 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by €4.0m. Reported Earnings • Feb 14
Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022) Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Duyuru • Dec 12
Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business.
Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023. Board Change • Dec 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022) Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to stay flat during the next 3 years compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 08
Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023 Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022. Duyuru • Aug 13
Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023 Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023 Reported Earnings • Aug 09
Second quarter 2023 earnings released: EPS: US$1.16 (vs US$1.30 in 2Q 2022) Second quarter 2023 results: EPS: US$1.16 (down from US$1.30 in 2Q 2022). Revenue: US$480.4m (up 2.7% from 2Q 2022). Net income: US$28.9m (down 11% from 2Q 2022). Profit margin: 6.0% (down from 6.9% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 2 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 07
Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023 Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023 Upcoming Dividend • May 12
Upcoming dividend of US$0.69 per share at 1.4% yield Eligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.6%). Duyuru • May 05
Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023 Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023. Reported Earnings • May 04
First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022) First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 2.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Mar 03
President recently sold €1.9m worth of stock On the 28th of February, Patrick Williams sold around 18k shares on-market at roughly €104 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months. Reported Earnings • Feb 23
Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021) Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 11
Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023 Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023 Recent Insider Transactions • Dec 07
Senior VP recently bought €77k worth of stock On the 5th of December, David Jones bought around 752 shares on-market at roughly €103 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €610k more in shares than they bought in the last 12 months. Reported Earnings • Nov 10
Third quarter 2022 earnings released: EPS: US$1.56 (vs US$0.95 in 3Q 2021) Third quarter 2022 results: EPS: US$1.56 (up from US$0.95 in 3Q 2021). Revenue: US$513.0m (up 36% from 3Q 2021). Net income: US$38.7m (up 65% from 3Q 2021). Profit margin: 7.5% (up from 6.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.3% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 09
Innospec Inc. Declares Semi-Annual Dividend, Payable on November 28, 2022 Innospec Inc. announced that it has declared a semi-annual dividend of 65 cents per common share for the second half of 2022 which will be paid on November 28, 2022 to shareholders of record as of November 21, 2022. This brings the annual dividend to $1.28 per share, a 10% increase over 2021. Duyuru • Oct 07
Innospec Inc. to Report Q3, 2022 Results on Nov 08, 2022 Innospec Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 08, 2022 Reported Earnings • Aug 03
Second quarter 2022 earnings released: EPS: US$1.30 (vs US$0.91 in 2Q 2021) Second quarter 2022 results: EPS: US$1.30 (up from US$0.91 in 2Q 2021). Revenue: US$467.6m (up 32% from 2Q 2021). Net income: US$32.3m (up 44% from 2Q 2021). Profit margin: 6.9% (up from 6.3% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.7%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 8% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jul 08
Innospec Inc. to Report Q2, 2022 Results on Aug 02, 2022 Innospec Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 02, 2022 Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improved over the past week After last week's 15% share price gain to €89.50, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in Germany. Total returns to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €40.04 per share. Reported Earnings • May 05
First quarter 2022 earnings released: EPS: US$1.47 (vs US$0.95 in 1Q 2021) First quarter 2022 results: EPS: US$1.47 (up from US$0.95 in 1Q 2021). Revenue: US$472.4m (up 39% from 1Q 2021). Net income: US$36.5m (up 56% from 1Q 2021). Profit margin: 7.7% (up from 6.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.5%, compared to a 8.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Duyuru • May 05
Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2022, Payable on May 26, 2022 Innospec Inc. announced the declaration of its semi-annual dividend of 63 cents per common share for the first half of 2022, representing an increase of 11% This dividend will be paid on May 26, 2022, to shareholders of record on May 17, 2022. Duyuru • Apr 07
Innospec Inc. to Report Q1, 2022 Results on May 03, 2022 Innospec Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022 Recent Insider Transactions • Mar 04
President recently sold €601k worth of stock On the 25th of February, Patrick Williams sold around 7k shares on-market at roughly €85.90 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €2.2m. Duyuru • Feb 18
Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares. Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock. The program will run over the next three years from commencement date. Reported Earnings • Feb 16
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: US$3.78 (up from US$1.17 in FY 2020). Revenue: US$1.48b (up 24% from FY 2020). Net income: US$93.1m (up 224% from FY 2020). Profit margin: 6.3% (up from 2.4% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 5.2%, compared to a 6.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Duyuru • Jan 06
Innospec Secures China Approval for Its Ultra-Mild, Sulfate-Free Iselux® Surfactants Innospec announces that Iselux® has been approved for use in China, the world’s second large personal care market. Available in liquid and solid form, Iselux® is a highly versatile, clear, mild and natural surfactant which delivers superior lather, skin feel and cleansing performance in more than 3,000 body, hair and other personal care products today. With the China approval secured, for the first time Iselux® is now available for worldwide cosmetic and personal care use by Innospec’s customers. Innospec technologies like Iselux® directly address growing long-term consumer demand for clean beauty without any compromise in product performance. Innospec recently announced plans for over $70MM of organic growth investments to be made through 2023 to support the increased demand outlook for its premium personal and home care technologies. Recent Insider Transactions • Nov 15
President recently sold €968k worth of stock On the 9th of November, Patrick Williams sold around 12k shares on-market at roughly €80.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €1.6m. Reported Earnings • Nov 04
Third quarter 2021 earnings released: EPS US$0.95 (vs US$0.52 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$376.1m (up 42% from 3Q 2020). Net income: US$23.4m (up 84% from 3Q 2020). Profit margin: 6.2% (up from 4.8% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Aug 04
Second quarter 2021 earnings released: EPS US$0.91 (vs US$1.62 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$354.5m (up 45% from 2Q 2020). Net income: US$22.4m (up US$62.1m from 2Q 2020). Profit margin: 6.3% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Recent Insider Transactions • May 13
President recently sold €382k worth of stock On the 7th of May, Patrick Williams sold around 5k shares on-market at roughly €83.67 per share. This was the largest sale by an insider in the last 3 months. Patrick has been a seller over the last 12 months, reducing personal holdings by €928k. Reported Earnings • May 06
First quarter 2021 earnings released: EPS US$0.95 (vs US$1.35 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$339.6m (down 8.8% from 1Q 2020). Net income: US$23.4m (down 29% from 1Q 2020). Profit margin: 6.9% (down from 8.9% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Duyuru • May 05
Innospec Inc. Announces Semi-Annual Dividend for the First Half of 2021, Payable on May 26, 2021 Innospec Inc. announced the declaration of its semi-annual dividend of $0.57 per common share for the first half of 2021, representing an increase of 10%. This dividend will be paid on May 26, 2021, to shareholders of record on May 17, 2021. Executive Departure • May 04
Senior Vice President of Corporate Development & Investor Relations Brian Watt has left the company On the 30th of April, Brian Watt's tenure as Senior Vice President of Corporate Development & Investor Relations ended after 3.7 years in the role. We don't have any record of a personal shareholding under Brian's name. A total of 2 executives have left over the last 12 months. Duyuru • Mar 20
Innospec Inc., Annual General Meeting, May 05, 2021 Innospec Inc., Annual General Meeting, May 05, 2021, at 10:00 US Eastern Standard Time. Agenda: To consider election of two Class II Directors; to consider ratification of the election of one Class I Director; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm. Is New 90 Day High Low • Feb 26
New 90-day high: €84.00 The company is up 17% from its price of €71.50 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. Duyuru • Feb 26
Brian Watt Informs His Decision to Retire as Senior Vice President, Corporate Development and Investor Relations of Innospec Inc., Effective April 30, 2021 On February 23, 2021, Mr. Brian Watt, Senior Vice President, Corporate Development and Investor Relations of Innospec Inc. (the 'Company'), informed the Company of his decision to officially retire effective April 30, 2021. The Company is discussing with Mr. Watt the possibility of him providing various support after his retirement. Reported Earnings • Feb 19
Full year 2020 earnings released: EPS US$1.17 (vs US$4.58 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$1.19b (down 21% from FY 2019). Net income: US$28.7m (down 74% from FY 2019). Profit margin: 2.4% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 19
Revenue beats expectations Revenue exceeded analyst estimates by 2.3%. Over the next year, revenue is forecast to grow 9.4%, compared to a 5.1% growth forecast for the Chemicals industry in Germany. Duyuru • Jan 19
Innospec Inc. to Report Q4, 2020 Results on Feb 16, 2021 Innospec Inc. announced that they will report Q4, 2020 results After-Market on Feb 16, 2021 Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improved over the past week After last week's 16% share price gain to US$83.00, the stock is trading at a trailing P/E ratio of 66.3x, up from the previous P/E ratio of 57.1x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 45%. Is New 90 Day High Low • Jan 08
New 90-day high: €78.00 The company is up 37% from its price of €57.00 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €26.34 per share. Is New 90 Day High Low • Dec 19
New 90-day high: €73.50 The company is up 30% from its price of €56.50 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.44 per share. Valuation Update With 7 Day Price Move • Nov 26
Market bids up stock over the past week After last week's 17% share price gain to US$72.00, the stock is trading at a trailing P/E ratio of 57.7x, up from the previous P/E ratio of 49.3x. This compares to an average P/E of 27x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%. Is New 90 Day High Low • Nov 16
New 90-day high: €69.00 The company is up 10.0% from its price of €63.00 on 18 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €130 per share. Valuation Update With 7 Day Price Move • Nov 16
Market bids up stock over the past week After last week's 19% share price gain to US$69.00, the stock is trading at a trailing P/E ratio of 52.7x, up from the previous P/E ratio of 44.3x. This compares to an average P/E of 26x in the Chemicals industry in Germany. Total returns to shareholders over the past three years are 24%. Upcoming Dividend • Nov 09
Upcoming Dividend of US$0.52 Per Share Will be paid on the 25th of November to those who are registered shareholders by the 16th of November. The trailing yield of 1.5% is below the top quartile of German dividend payers (3.8%), and is lower than industry peers (4.4%). Reported Earnings • Nov 05
Third quarter 2020 earnings released: EPS US$0.52 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$265.1m (down 29% from 3Q 2019). Net income: US$12.7m (down 58% from 3Q 2019). Profit margin: 4.8% (down from 8.1% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year. Analyst Estimate Surprise Post Earnings • Nov 05
Revenue misses expectations Revenue missed analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 2.3% growth forecast for the Chemicals industry in Germany. Duyuru • Nov 03
Innospec Inc. Appoints Elizabeth Keller Arnold as A Non-Employee Director Innospec Inc. announced that it has appointed Ms Elizabeth Keller Arnold as a non-employee director, effective November 1, 2020. After a long and successful career with General Electric and Tyco, Ms. Arnold was most recently Chief Financial Officer of Houghton International, a highly regarded global specialty chemical company. She is also an independent director of FreightCar America Inc. She has been appointed for an initial term until the 2021 Annual Stockholders Meeting and will also become a member of the Audit Committee. Duyuru • Oct 08
Innospec Inc. to Report Q3, 2020 Results on Nov 03, 2020 Innospec Inc. announced that they will report Q3, 2020 results at 5:00 PM, GMT Standard Time on Nov 03, 2020 Is New 90 Day High Low • Sep 25
New 90-day low: €53.00 The company is down 18% from its price of €64.50 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €120 per share. Duyuru • Jul 08
Innospec Inc. to Report Q2, 2020 Results on Aug 04, 2020 Innospec Inc. announced that they will report Q2, 2020 results at 5:00 PM, GMT Standard Time on Aug 04, 2020